We have examined the role of intrapulmonary TNF in a rat model of acute immune complex-triggered alveolitis. Intratracheal instillation of IgG anti-bovine serum albumin (anti-BSA) followed by intravenous infusion of BSA results in acute alveolitis. Over the 4-h course of evolving lung injury, a 10-fold increase in TNF activity occurred in bronchoalveolar lavage (BAL) fluid. Immunohistochemical analysis of lung sections and BAL cells revealed that alveolar macrophages are the chief source of TNF. Antibodies that specifically neutralize rat TNF activity were raised in rabbits immunized with recombinant mouse TNFa. When administered into the lungs with anti-BSA, anti-TNF resulted in a marked reduction (up to 61%) in lung injury. Intratracheal instillation of exogenous TNF alone, or in combination with anti-BSA, resulted in an increase in lung injury compared to controls. Morphometric analysis and measurements of myeloperoxidase activities in whole lung extracts from rats treated with anti-TNF revealed a marked reduction in neutrophils compared to positive controls. The anti-TNF antibody preparation did not inhibit in vitro complement activation or diminish neutrophil chemotactic activity present in activated rat serum. These data indicate that intrapulmonary TNF activity is required for the full development of acute immune complex-triggered alveolitis, that alveolar macrophages are the primary source of this cytokine, and that TNF participates in the pathogenesis of immune complex alveolitis through a mechanism involving neutrophil recruitment.
Introduction
Tumor necrosis factor (TNF)1 is a hormone-like polypeptide that possesses a wide range of metabolic, immunologic and inflammatory activities (reviewed in 1). Once attributed to the direct effects of bacterial endotoxin, many of the metabolic and physiologic derangements of endotoxic and septic shock are thought to be mediated by endogenous cytokines, notably TNF. Physiologically significant, even lethal, quantities of TNF have been detected in the sera ofanimals after infusion of endotoxin or viable bacteria (2, 3) . Studies in several mammalian species have shown that most of the pathophysiologic manifestations of endotoxemic shock can be reproduced by injection of recombinant TNF (2, (4) (5) (6) (7) . Passive immunization of mice and rabbits with anti-TNF antibodies before infusion oflethal doses ofendotoxin attenuates major pathophysiologic manifestations of endotoxic shock and reduces the incidence of endotoxin-mediated death (4, 8) .
It has been proposed that locally regulated generation of TNF at sites of injury represents an important autocrine-paracrine control mechanism operative in acute inflammatory responses. In vitro studies suggest that TNF is chemotactic for neutrophils (9) , induces their degranulation (10) , induces their adhesion to endothelium (1 1), and stimulates their release of oxygen-derived metabolites (10, 12) . TNF also activates macrophages resulting in IL-1 and PGE2 production (13), augmented cytotoxic potential (14, 15) , and enhanced superoxide anion production after exposure to immune complexes (16) . TNF has been shown to directly increase endothelial cell procoagulant activity by several mechanisms (17) (18) (19) (20) (21) . TNF induces the synthesis of endothelial cell surface factors that increase neutrophil adherence to the endothelial surface through mechanism(s) dependent on subunits of the neutrophil membrane adhesion complex CDwl 8 (Mac-I/LFA-I/p1 50,95) (1 1, 22). Horvath et al. (23) have shown that intravenous infusion of human TNF into sheep results in increases in pulmonary vascular resistance, transvascular fluid filtration, and transvascular protein clearance. Both in vivo and in vitro studies suggest that TNF increases endothelial permeability to proteins through a neutrophil-independent mechanism (23) . TNF has also been reported to trigger platelet-activating factor synthesis by endothelial cells (24) . Recently, Strieter et al. (25) demonstrated that TNF can stimulate endothelial cell production of a 7,500-D neutrophil chemotactic factor (NCF) and mRNA transcripts that encode NCF. Although TNF appears to be an important mediator in the shock syndrome caused by infusion oflive bacteria or bacterial endotoxin and apparently modulates a variety of inflammatory cell functions, the role of TNF in compartmentalized acute inflammatory processes in vivo has been studied only preliminarily. A synergistic effect between TNF and IL-1 has been described in the induction of Shwartzman-like reactions (26) and in the induction of neutrophil emigration (27) , while studies of neutrophil emigration triggered by intradermal endotoxin injections suggest that TNFa by itself does not mediate neutrophil emigration (28). In mice, intradermal injection ofTNFa has been shown to trigger acute dermal inflammation (29) . These studies serve to emphasize the prevailing uncertainties surrounding the role of TNF in acute inflammation.
In the present study we examined the role of intrapulmonary TNF in the pathogenesis of acute immune complex-induced alveolitis in the rat. We sought to determine whether TNF is produced in the lung during the evolution of immune complex-induced lung injury, which pulmonary cells produce TNF, and to what extent this cytokine may contribute to the pathogenesis of acute alveolitis. The results of this study demonstrate that TNF is an important mediator of acute immune complex alveolitis and that it influences this process through a mechanism involving neutrophil recruitment.
Methods
Animal model ofimmune complex alveolitis. Male Long-Evans specific pathogen free rats (300-400 g; Charles River Breeding Laboratories, Inc., Wilmington, MA) were used for all studies. Intraperitoneal injections of ketamine (2.5-5.0 mg/100 g body wt) and sodium pentobarbital (5 mg/I00 g body wt) were given for sedation and anesthesia. Immune complex lung injury was induced as previously described (30, 31) . Antibody solutions (250 ug anti-BSA unless otherwise specified), recombinant mouse TNFa (Genzyme, Boston, MA), or mixtures of antibody and TNF, were instilled into the lungs via a tracheal cannula.
In all cases, a final volume of 200 tl was instilled into the lungs.
Antigen (BSA, 10 mg) was injected intravenously. Rats were sacrificed at the indicated times and BAL fluid harvested (see below) or lung injury quantitated. Pulmonary injury was quantitated by permeability measurements as well as by morphometric analysis. Permeability indices were calculated by comparing the leakage of '251-labeled bovine gamma globulin from the circulation into the lung to the counts per minute '251I-labeled colloid in 1 ml of blood as previously described (30) .
Collection ofBAL fluid and isolation ofalveolar macrophages. Alveolar macrophages were recovered from normal rats using a previously described modification of the method of Van Oud Alblas and Van Furth (32).
BAL contents for cytokine measurements and cellular function assays were collected using 5 ml of 370C, serum-free RPMI 1640. At least 90% of the administered fluid was always recovered, centrifuged (400 g; 7 min) to remove cells, and stored at -20°C before analysis. Morphometric analysis of lung injury. Transmission electron micrographs were prepared from whole lungs fixed in 4% glutaraldehyde under constant pressure inflation (25 cm H20), washed in 0.1 M cacodylate buffer (pH 7.3), and embedded in plastic. 1-,um-thick sections were stained with toluidine blue and processed for transmission electron microscopy by using a 401 transmission electron microscope (401; Philips Electronic Instruments, Mahwah, NJ). As previously described (33) , morphometric analysis was carried out by an experienced electron microscopist (R. G. Kunkel) who was blinded to sample origin. For each condition five lung samples were examined. In each sample, 45-60 randomly selected 40X microscopic fields were analyzed.
Preparation ofIgG anti-BSA. Rabbit (or mouse) IgG rich in antibody directed against BSA was used to induce lung injury and to form precipitating polyclonal IgG-BSA immune complexes. Antibody content and production of immune complexes have been previously described in detail (30) . Briefly, IgG was prepared from hyperimmune serum by precipitation with saturated ammonium sulfate (50%), followed by dialysis against 0.005 M PBS and passage through a DEAE cellulose column. Where indicated, antibody was heat denatured (100°C, 20 min). The IgG anti-BSA and BSA (low endotoxin; ICN Biomedicals, Costa Mesa, CA) preparations contained < 0.02 ng/ml and 0.0 12 ng/ml of endotoxin activity, respectively, as estimated using the Limulus amebocyte lysate (LAL) assay (E-toxate; Sigma Chemical Co., St. Louis, MO). Antigen-antibody equivalence has previously been shown to occur at a 1:5 (wt/wt) ratio (30) .
Preparation of TNF and IL-I-rich conditioned medium from alveolar macrophages. Rat alveolar macrophages were suspended in RPMI 1640 (KC Biological, Lenexa, KS), supplemented with 100 U/ml penicillin, 100 gg/ml streptomycin, 300 gg/ml fresh glutamine, and 10% heat-inactivated fetal calf serum (FCS; Gibo Laboratories, Grand Island, NY). Alveolar macrophages (2 X 106/ml) were plated in 35-mm polystyrene dishes (Corning Glass Works, Corning, NY) and maintained in a humidified 5% CO2 atmosphere at 370C to allow macrophages to adhere. After 2 h, the dishes were gently washed twice with serum-free 370C RPMI 1640 and Escherichia coli lipopolysaccharide 0111 :B4 (Sigma Chemical Co.) (10 gg/ml) was added to culture dishes. The dishes were maintained for 4 Preparation ofIgG anti-TNF antibodies. Anti-TNF alpha was produced by immunization of rabbits with recombinant murine TNF as previously described (36) . The resulting antiserum was affinity purified using a protein A Sepharose column (Sigma). Anti-TNF serum was diluted 1: 1 with PBS (I100 mM phosphate, pH 8.0, 150 mM NaCl) and applied slowly to the PBS-washed column. After extensive washing with PBS, the column was stripped with 100 mM sodium acetate buffer, pH 3.0. l-ml fractions were collected in tubes containing 50 Al of 1 M Tris buffer, pH 8 .0. The affinity purified IgG fraction was then dialyzed against PBS and characterized as described below.
Western immunoblot analysis ofanti-TNF. Recombinant murine IL-lI3 (100 ng), IL-la (200 ng), and TNFa (200 ng) were electrophoresed in 12.5% SDS-PAGE with a 7% stacking gel according to the method of Laemmli (37) . The electrophoretically separated proteins were transblotted to nitrocellulose (0.45 ,im; Bio-Rad Laboratories, Richmond, CA) for 20 min at 24 V with a Genie transblot apparatus (Idea Scientific, Corvallis, OR). After transfer, the gel was blocked by treatment with Tween-Tris-buffered saline ([T-TBS], 20 mM Tris-HC1, pH 7.5, 500 mM NaCi, 0.05% vol/vol Tween) containing 5% lowfat milk and 1% normal goat serum for 1 h. The gel was twice washed with T-TBS, followed by addition for 1 h of purified rabbit anti-mouse TNF at a final concentration of 1 Ag/ml. The gel was then washed twice with T-TBS followed by addition of biotinylated goat anti-rabbit IgG (1:3,000) for 1 h. After two additional washes, streptavidin-alkaline phosphatase complex was added for 1 h, the nitrocellulose washed, and bands developed. Biotinylated protein standards were used to assess molecular weights.
Immunohistochemical analysis oflung sections and BAL cells. Immunochemical analyses of lung sections and BAL cells were carried out using adaptations of previously described methods (36) . In order to avoid potential binding of biotinylated secondary antibody (goat antirabbit) to the rabbit anti-BSA routinely used to induce alveolitis, mouse IgG anti-BSA was substituted. Comparison studies have shown rabbit and mouse IgG anti-BSA preparations to be indistinguishable in this model system (data not shown).
At the indicated times after induction of lung injury, a 3:1 mixture (vol/vol) of OCT embedding medium (Miles Laboratories, Naperville, IL) and PBS (10 mM, pH 7.4) was instilled into whole rat lungs, which were then frozen (-20'C). Frozen sections were fixed for 10 min in acetone, rehydrated with PBS, and fixed (3 min) in absolute methanol. The slides were rinsed again with PBS and treated with a 1:50 dilution of normal goat serum for 10 min at 370C, then decanted and exposed to a 1:1,000 dilution ofanti-TNFa or a similar dilution ofnonimmune rabbit serum. After 20 min of incubation at 370C, the slides were rinsed three times with PBS, then overlaid with biotinylated goat antirabbit IgG (1:100) (Vector Laboratories, Burlingame, CA) and incubated another 10 min, followed by three additional rinses with PBS. The slides were next treated with alkaline phosphatase labeled streptavidin and levamisole (endogenous alkaline phosphatase inhibitor), incubated again, rinsed three times, then overlaid with substrate chromogen (Kit I, Vector Red) for 5 min at 37°C to allow for color development. Mayer's hematoxylin was used as a counterstain.
In separate experiments, BAL cells were harvested 0, 1, 2.5, and 4 h after initiation of lung injury. The cells were washed and suspended in serum-free RPMI 1640 at 106 cells/ml. Cells (250 Al) were then added to 8-well slide tissue culture chambers (Lab-Tek, Miles Laboratories) at 37°C in 5% C02, humidified atmosphere. After 1 h, nonadherent cells were rinsed away with warm RPMI 1640. BAL cell monolayers were fixed and stained as described above except that the slides were treated with 3% hydrogen peroxide solution to inactivate any remaining endogenous peroxidase activity. After treatment ofthe slides with biotinylated anti-rabbit IgG, the slides were treated with peroxidase-labeled streptavidin (Sigma Chemical Co.) and developed with 3-amino-9-ethylcarbazole. Whole lung myeloperoxidase activities. Whole lungs were homogenized with a Polytron homogenizer (4 X 10 s at a setting of 4) using 6 ml of homogenization buffer. The homogenization buffer (50 mM phosphate, pH 6.0) contained 0.5% hexadecyltrimethyl ammonium bromide (Sigma) and 5 mM EDTA. Homogenized samples were then sonicated (3 X lO s at a setting of 5) and centrifuged (3,000 X g; 30 min) at 4°C. Myeloperoxidase activity in supernatants was assayed by measuring the change in A460 resulting from decomposition of H202 in the presence of o-dianisidine (38) .
Neutrophil chemotaxis and serum activation. Heparinized caval blood was collected from Long-Evans rats and the neutrophils isolated by centrifugation over a Histopaque-1077 gradient (Sigma) after sedimentation of red blood cells with hydroxy ethyl starch (6% Volex; McGaw Laboratories, Glendale, CA) (39) . Residual erythrocytes were removed by hypotonic lysis. The purified neutrophils (83-86% by Wright stain morphology) were suspended at 1.5 X 106/ml in HBSS with calcium (1.8 mM), magnesium (0.8 mM) and 1% BSA. Chemotaxis was performed in blind multi-well Boyden chemotactic chambers (40) . 225 ,l HBSS was placed in the bottom well with either HBSS alone, zymosan (0.1 mg/ml) activated rat serum (25 5 ities were assayed from TIME (hours)
IgG immune complexinjured rats (o), negative control rats (nonspecific intratracheal IgG) (e), and noninjured (normal) rats (A). The data expressed represent means±SEM of three experiments in which three to five animals were employed for each variable. For normal rats, three animals were employed in a single experiment. Data were analyzed by one-way analysis of variance with significance assigned for P < 0.05 (46) . * Indicates significant differences versus injured rats at time zero, negative control rats, and normal rats.
free; Nucleopore Corp., Pleasanton, CA) was placed in the assembly and 333 Ml of neutrophil suspension placed in the top chamber. The neutrophils were incubated at 370C in a humidifed chamber. The filters were removed and stained with Diff-Quik (Baxter Corp., Chicago, IL). Locomotion indices were calculated as described by Maderazo et al. (41) . Experiments addressing the effects of anti-TNF on serum activation were conducted similarly, except that varying concentratidns of anti-TNF or control antibody were added to rat serum during exposure to zymosan. The resulting supernatants were then assayed for chemotactic activity.
Results
Elaboration ofintrapulmonary TNF during IgG immune complex-induced lung injury. Bronchoalveolar lavage (BAL) fluids were examined for the presence of TNF as a function of time after airway instillation of anti-BSA and intravenous infusion of antigen. It is apparent that very little increase in TNF activity could be detected in the first 2 h (Fig. 1 ). After this time there was a rapid rise in BAL TNF activity; by 4 h, TNF levels had increased 10-fold. In animals that received anti-BSA in the absence of antigen or heat-denatured anti-BSA in the presence 150- Figure 2 . Immunohistochemical localization of TNF production in acute alveolitis. Immunohischemical studies were carried out to determine the in vivo source(s) of intrapulmonary TNF elaboration during the development of immune complex alveolitis. Examination of lung sections obtained 0, 1, 2.5, and 4 h after induction of lung injury revealed a progressive increase in the proportion of alveolar macrophages that stained positively for TNF (Fig. 3) . At each time point, TNF activity appeared to be largely restricted to alveolar macrophages.
In a separate experiment, immune complex lung injury was induced and BAL cells were harvested after 0, 1, 2.5, or 4 h. Samples of BAL cells were placed into 8-well slide tissue culture chambers, where after 1 h, nonadherent cells were 150 Figure 4 . In vitro neu- In vitro neutralization of rat TNF activity with specific anti-TNF antibodies. Specific anti-murine TNF antibodies were raised in rabbits immunized with recombinant mouse TNFa. Immunoblot analysis ofthe anti-TNF revealed reactivity with TNF and the absence of reactivity with either IL-I a or IL-113 (data not shown). In order to permit analysis of the role of TNF in immune complex alveolitis we examined the capacity of this antibody preparation to specifically neutralize rat TNF activity.
Aliquots of serum-free TNF and IL-1-rich conditioned medium from rat alveolar macrophage cultures were used to test the neutralizing capacity of the anti-TNF antibody and to verify the absence of cross-reactivity with a potentially relevant cytokine, IL-1. Affinity purified IgG anti-TNF antibodies blocked rat TNF activity in a dose-dependent manner (Fig. 4) . Equivalent concentrations of irrelevant affinity purified rabbit IgG had no neutralizing effect on rat TNF activity. Likewise, addition of heat-inactivated preimmune rabbit serum had no inhibitory effect on TNF activity. The negligible differences in TNF activity present in aliquots incubated with preimmune serum versus TNF activity present in aliquots not exposed to any added serum or antibody suggest that the presence of IgG per se does not influence measurements of TNF activity. Neither anti-TNF (72 ,g), irrelevant rabbit IgG (72 ,ug), nor preimmune rabbit serum had any blocking effect on IL-1 activity present in conditioned medium.
Blockade ofIgG immune complex alveolitis with anti-TNF antibodies. Intratracheal instillation of anti-TNF resulted in a 61% reduction in IgG immune complex induced lung injury (Fig. 5) . pulmonary vascular permeability as determined by leakage of '25l-labeled colloid into the airspace and lung parenchyma (30) . Substitution of equivalent concentrations of heat-inactivated anti-TNF or nonspecific rabbit IgG for anti-TNF failed to suppress immune complex lung injury (< 10% reduction) suggesting that the anti-TNF antibodies exerted a specific neutralizing effect. Lung permeability indices in rats that received sterile saline in place of nonspecific IgG or preimmune serum were all similar (< 10% difference) suggesting that there was no suppression of lung injury attributable to a nonspecific "protective effect" of protein instilled into the lungs (data not shown). To confirm that intratracheal instillation of anti-TNF neutralized intrapulmonary TNF, we measured BAL fluid TNF activity 4 h after lung injury was induced in the presence of the blocking antibody preparation. Instillation of intratracheal anti-TNF resulted in nearly complete neutralization of intrapulmonary (BAL) TNF activity (Fig. 6) .
Effect of added TNF on the development of lung injury. Recombinant mouse TNFa was instilled into the lungs of rats in order to determine whether exogenous TNF directly induces lung injury. Instillation of mouse TNF quantities equivalent to the maximum endogenous TNF activities measured in BAL fluid during evolving immune complex alveolitis resulted in modest increases in pulmonary vascular permeability (Table II) . Histologic examination of lung sections revealed small, scattered foci of intraalveolar hemorrhage and neutrophil accumulation within alveolar septae (data not shown). Mouse TNF was also mixed with anti-BSA to determine whether the addition ofexogenous TNF exhances the development of immune complex alveolitis. In these experiments, submaximal lung injury was induced by reducing the intratracheal anti-BSA from 250 to 80 Mg. As shown in Table II , the addition of exogenous TNF to anti-BSA resulted in a small, dose-dependent augmentation of immune complex lung injury. These experiments provide additional evidence that TNF participates in the pathogenesis of acute immune complex alveolitis in the rat.
Evidence that TNF contributes to lung injury through a neutrophil-mediated mechanism. Transmission electron micrographs of lung sections from rats with immune complex alveolitis revealed the expected extensive intraalveolar hemorrhage and large neutrophil influx. In contrast, rats that received anti-TNF (30 ,g) exhibited a marked reduction in intraalveolar hemorrhage and a striking reduction in neutrophils (Fig. 7) . Morphometric analysis of lung sections confirmed the diminished neutrophil influx and hemorrhagic changes in lungs of rats treated with anti-TNF (Table III) .
Another method for measuring neutrophil content in lungs was also employed. Whole lungs from rats in each of the treatment groups were homogenized and assayed for myeloperoxidase activity (Table IV) . There was a marked reduction in the myeloperoxidase activity present in lungs from rats treated with anti-cytokine antibodies compared with positive control animals. These data suggest that TNF is necessary for the recruitment of neutrophils into lungs of animals developing immune complex alveolitis.
Anti-TNF does not impair rat complement activation or chemotactic activity in activated serum. Measuring migrational responses of rat neutrophils, relevant concentrations of anti-TNF did not impair the chemotactic activity contained in rat serum that had been activated with zymosan (Table V) .
Similarly, incubation of anti-TNF (43 ,ug) with fresh rat serum (25 Ml) did not impair complement activation by zymosan particles (0.1 mg/ml) as measured by rat neutrophil chemotaxis (data not shown). These experiments provide evidence that the anti-TNF antibody preparation does not interfere with The in vivo studies summarized in Fig. 5 demonstrate that intrapulmonary instillation of anti-TNF results in marked attenuation of immune complex-mediated lung injury. The specificity and neutralizing capacity of anti-TNF, in conjunction with the lack of suppressive effects exhibited by control antibodies, strongly suggest that intrapulmonary TNF plays a major role in the pathogenesis of immune complex alveolitis. This conclusion is further supported by the observation that the intrapulmonary instillation of exogenous TNF, either alone or with anti-BSA, can recapitulate or amplify the lung injury associated with alveolar immune complex deposition.
Morphometric analysis of intraalveolar hemorrhage corroborates the pulmonary vascular permeability data and provides evidence that the differences in permeability between protected and unprotected rats reflect differences in lung injury, not solely net differences in transcapillary solute transport. Morphometric analysis revealed a striking reduction in neutrophils in lungs of rats treated with anti-TNF. Whole lung myeloperoxidase activity measurements confirmed the marked reduction in pulmonary neutrophil influx. The reduction in intraalveolar hemorrhage observed in rats treated with anti-TNF does not preclude the possibility that TNF directly influences transvascular protein clearance distinct from capillary disruption due to neutrophil-mediated tissue injury. Recent studies by Horvath et al. (23) indicate that infusions of TNFa into sheep result in increased pulmonary transvascular protein clearance through a mechanism independent of neutrophils. These investigators suggest that TNF may play a role in pulmonary microvascular leakage through neutrophil-independent process(es). Anti-TNF does not impair complement activation or the chemotactic activity present in zymosan-activated serum. These experiments provide evidence against the possibility that anti-TNF antibodies directly interfere with complement-mediated neutrophil recruitment.
The salient mechanism(s) involved in TNF mediated neutrophil influx are not known in this model, but several activities ascribed to this cytokine could play a role. While it is clear that TNF is linked to neutrophil influx, it is unknown whether this effect is direct or indirect. For instance, TNF is thought to be chemotactic for neutrophils (9) although this action is debated (44) . TNF induces the expression of endothelial and neutrophil adhesion molecules (11, 22) which appear to be critical in directing neutrophils into inflammatory sites. TNF can trigger endothelial cells to produce platelet-activating factor (24) , which in turn is chemotactic for neutrophils (45) . Recently, Strieter et al. (25) have shown that TNF can induce the synthesis of a neutrophil chemotactic factor by several types of cells that are indigenous to the lung. It is possible that the requirement for TNF is related to the sequential actions of more than one cytokine. For instance, TNF can trigger IL-1 and IL-6 production by endothelial cells and fibroblasts (1) . In this scenario, neutralization of TNF would prevent elaboration of other cytokines. The present studies support the concept that locally elaborated TNF plays a major role in regulating a compartmentalized acute inflammatory response. Further investigation will be required to determine the precise relationships between TNF and other important proinflammatory mediator systems.
